For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A021502

Trial Overview

Official Title

Testing the Addition of the Antibody Atezolizumab to Usual Chemotherapy after Surgery in Patients with Colon Cancer

Study Purpose

To compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone.

Diagnosis

Stage III Colon cancer

Eligibility

Stage III colon cancer that has been removed by surgery.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: Chemotherapy plus atezolizumab for 6 months, then atezolizumab alone for 6 months

  • Group 2: Chemotherapy for 6 months

  • Quality of Life surveys

After completion of the study patients will be followed for 8 years

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
A021502
Related Specialties